PathAI
AI-powered pathology platform to improve patient outcomes through precision diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
AI-powered pathology algorithmsLarge proprietary pathologist contributor network (450+ board-certified pathologists)Extensive annotation dataset (32.5M+ annotations)FDA-cleared digital pathology platform (AISight® Dx)CE-IVDR marked platformBiomarker discovery and drug development supportCloud-native open platform enterprise workflow (AISight®)
Enterprise pricing
Boston, USA
Founded 2016
Facts verified against pathai.com on
Get alerts when PathAI changes
Free. We'll email you when pricing, the free tier, API access or open-source status changes.
No ratings yet
PathAI – Technical Documentation Notes
Developers and technical evaluators working with PathAI should be aware of the following platform characteristics:
- AISight® is architected as a cloud-native, open platform, designed to integrate into existing enterprise anatomic pathology workflows without requiring a closed ecosystem.
- AISight® Dx carries both FDA clearance and CE-IVDR marking, supporting compliant clinical deployment across US and European regulatory jurisdictions.
- The platform supports third-party algorithm integrations, with confirmed partners including Deep Bio, Paige, Visiopharm, and DoMore Diagnostics, indicating an open or semi-open API/plugin model for algorithm ingestion.
- PathAI's AI algorithms are trained on a proprietary annotation dataset of 32.5M+ annotations sourced from 450+ board-certified pathologists, providing a high-quality, expert-labeled training corpus.
- The platform is positioned to support biomarker discovery and drug development use cases, relevant for BioPharma technical and data science teams building computational pathology pipelines.
Alternatives
See all alternatives Alternatives to PathAI
Is PathAI yours? Claim the listing & get the badge